As RIP2 knockdown by itself has little effect on cell growth in vitro (Figure 6B), we used docetaxel (one of the most common chemotherapies given for breast cancer) to determine if RIP2 knockdown would chemosensitize tumor cells to docetaxel. The gene discussed is RIPK2; the disease is neoplasm.